Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17807738 | 0.85 | MTOR (0.58) | MTORCYP1A2FYNPOLBMEN1 | |
| SCHEMBL975769 | 0.81 | CYP1A2 (0.64) | MTORCYP1A2FYNHSD17B10L3MBTL1 | |
| SCHEMBL18898643 | 0.80 | MTOR (0.55) | MTORCYP1A2FYNCDK1L3MBTL1 | |
| SCHEMBL481934 | 0.77 | MTOR (0.58) | MTORCYP1A2FYNCDK1POLB | |
| SCHEMBL24995677 | 0.74 | MTOR (0.55) | MTORCYP1A2FYNPOLBMAPK8 | |
| SCHEMBL975519 | 0.74 | MTOR (0.55) | MTORCYP1A2FYNPOLBALDH1A1 | |
| SCHEMBL975243 | 0.72 | CYP1A2 (0.51) | MTORCYP1A2FYNALDH1A1ADORA2B | |
| SCHEMBL975242 | 0.72 | CYP1A2 (0.51) | MTORCYP1A2FYNALDH1A1ADORA2B | |
| SCHEMBL978467 | 0.72 | CYP1A2 (0.51) | MTORCYP1A2FYNALDH1A1ADORA2B | |
| SCHEMBL977402 | 0.72 | MTOR (0.53) | MTORCYP1A2FYNPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010556-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | MTOR 2397/4885CYP1A2 4220/4885FYN 2781/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MTOR 2445/4885CYP1A2 4563/4885FYN 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.